Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Closing the quality gap: revisiting the state of the science (vol. 4: medication adherence interventions: comparative effectiveness).
Unmet Needs of Patients Feeling Severely Affected by Multiple Sclerosis in Germany: A Qualitative Study.
Participation of interleukin 17A in neuroimmune interactions.
Ginsenoside Rd ameliorates experimental autoimmune encephalomyelitis in C57BL/6 mice.
Vital role of specialist MS nurses recognised in proposed guideline.
Immunomodulatory effects of 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors, potential therapy for relapsing remitting multiple sclerosis.
Age-associated changes in rat immune system: Lessons learned from experimental autoimmune encephalomyelitis.
Iron deposition in the precentral grey matter in patients with multiple sclerosis: A quantitative study using susceptibility-weighted imaging.
S1P and the birth of platelets.
Next-generation sequencing in understanding complex neurological disease.
Vitamin D as a clinical biomarker in multiple sclerosis.
Cerebrospinal fluid concentrations of ghrelin in patients with multiple sclerosis.
Brain abnormalities in neuromyelitis optica spectrum disorder.
Immunosuppressive monoclonal antibody to CD64 from patients with long-term stable multiple sclerosis.
Pharmacodynamic Consequences of Administration of VLA-4 Antagonist CDP323 to Multiple Sclerosis Subjects: A Randomized, Double-Blind Phase 1/2 Study.
[Natalizumab in the treatment of patients with relapsing-remitting multiple sclerosis: the preliminary results of the observational program "Sovet"]
Serum Biomarker gMS-Classifier2: Predicting Conversion to Clinically Definite Multiple Sclerosis.
Distinguishing Optic Neuritis in Neuromyelitis Optica Spectrum Disease From Multiple Sclerosis: A Novel Magnetic Resonance Imaging Scoring System.
Preliminary results after upper cervical chiropractic care in patients with chronic cerebro-spinal venous insufficiency and multiple sclerosis.
Metabolic dysfunctions in multiple sclerosis: implications as to causation, early detection, and treatment, a case control study.
Optimizing therapy early in multiple sclerosis: An evidence-based view.
Diagnosis of atypical forms of chronic inflammatory demyelinating polyradiculoneuropathy: a practical overview based on some case studies.
Polyclonal immunoglobulin G for autoimmune demyelinating nervous system disorders.
Symptomatic Sinus Bradycardia After a Treatment Course Of High-dose Oral Prednisone.
Neuro-glial interactions at the nodes of Ranvier: implication in health and diseases.
Pages
« first
‹ previous
…
383
384
385
386
387
388
389
390
391
…
next ›
last »